Reverse-phase separation method for Fmoc-L-Val-OH and Fmoc-D-Val-OH

Through the combination of liquid chromatography and Cellu-DR chiral chromatography column, the problem of poor solvent hazards and separation effects in traditional amino acid detection was solved, and Fmoc-L-Val-OH and Fmoc-D-Val-OH were achieved. Efficient separation, meets the requirements of the pharmacopoeia and provides a high-sensitivity detection method.

CN118937550APending Publication Date: 2024-11-12THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411005963.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The organic solvents used in the detection of amino acids in traditional normal phase chromatography are very harmful, have high equipment maintenance costs, and are difficult to effectively separate Fmoc-L-Val-OH and its isomers, resulting in the production of impurities for the final product.

Method used

Fmoc-L-Val-OH and Fmoc-D-Val-OH were separated by reverse phase using liquid chromatography using Cellu-DR chiral chromatography column and specific mobile phase conditions (aqueous phosphoric acid solution and methanol at pH 2.00) to achieve the reverse phase separation of Fmoc-L-Val-OH to achieve Isometric elution, resolution greater than 1.5, meeting the requirements of the pharmacopoeia.

Benefits of technology

The separation of Fmoc-L-Val-OH and its isomers with stable baseline, good impurity separation effect and high sensitivity has been achieved, overcome the shortcomings of the traditional methods and provides reference for other analytical methods with protected amino acids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937550A_ABST
    Figure CN118937550A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of amino acid detection, in particular to a method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH. The method for separating and measuring Fmoc-L-Val-OH and the isomers of Fmoc-L-Val-OH is finally obtained by adopting a conventional and common reverse-phase solvent, selecting a # imgabs0 # Cellu-DR chiral chromatographic column to separate the isomers with protected amino acids, and determining a phosphoric acid aqueous solution with the pH value of 2.00 + / -0.1 as a mobile phase A and methanol as a mobile phase B, thereby obtaining the method for separating and measuring Fmoc-L-Val-OH and the isomers of Fmoc-L-Val-OH. When the method is used for separation, the separation degree of each component under the chromatographic condition is greater than 1.5, the separation is good, the baseline is stable, the impurity separation effect meets the requirements of pharmacopeia, the specificity is good, the sensitivity is high, the defects in the prior art are overcome, and reference is provided for development of analysis methods of other types of protected amino acids.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of amino acid detection, and in particular to a method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH. Background Art

[0002] Fmoc-L-Val-OH, chemical name: fluorenylmethoxycarbonyl-valine, is widely used in peptide synthesis. There are many suppliers in China, such as Chengdu Zhengyuan and Chengdu Taihe. Its structural formula is:

[0003]

[0004] During the solid phase synthesis reaction stage, the isomeric impurities in the Fmoc-L-Val-OH starting material can participate in the solid phase synthesis reaction process, which can eventually lead to the production of differential peptide impurities in the final product. According to the current regulations on peptide registration, the quality control of the starting amino acid material is required, including the control of isomeric impurities. The traditional method is to separate isomers through normal phase chromatography. However, the organic solvents used in the normal phase chromatography are highly harmful, and the liquid chromatography system needs to be switched, which causes great damage to certain components and pipelines of the liquid chromatography system, and the cost of equipment maintenance is high.

[0005] Therefore, in order to solve the above problems, it is currently a key research direction to find a method for separating and determining Fmoc-L-Val-OH and its isomers, which has a stable baseline, an impurity separation effect that meets the requirements of the pharmacopoeia, good specificity, high sensitivity, and can overcome the shortcomings of the existing technology. Summary of the invention

[0006] In order to solve the above technical problems existing in the prior art, the present invention provides a method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH, which is specifically achieved by the following technical scheme:

[0007] A method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH, using liquid chromatography for determination, the chromatographic conditions are as follows:

[0008] Chromatographic column: Cellu-DR chiral chromatographic column, its specifications are: 4.6mm*250mm, 5um.

[0009] Mobile phase: Aqueous phosphoric acid solution with a pH of 2.00±0.1 was used as mobile phase A, and methanol was used as mobile phase B.

[0010] Furthermore, other parameters are as follows:

[0011] Flow rate: 0.5±0.1ml / min; detection wavelength: 220nm.

[0012] Column temperature: 30±2℃; injection volume: 5.0±0.5 μl.

[0013] Blank solution: methanol.

[0014] Furthermore, the Cellu-DR chiral chromatographic column is a reverse phase chiral chromatographic column with the stationary phase being cellulose-tris(3,5-dimethylphenylcarbamate) coated on the silica surface.

[0015] The method for separating Fmoc-L-Val-OH and Fmoc-D-Val-OH by reverse phase separation adopts isocratic elution, and the elution procedure is as follows:

[0016]

[0017]

[0018] Further, the preparation method of the test solution is as follows: take the test sample, accurately weigh it, put it in a container, add the blank solution to dissolve and dilute it, shake well, and obtain. Specifically, take about 10 mg of the test sample, accurately weigh it, put it in a suitable container, add the blank solution to dissolve and dilute it to 10 ml, shake well, and obtain, and prepare two in parallel.

[0019] Further, the method for preparing the system adaptability solution is as follows: take the Fmoc-Val-OH reference substance, accurately weigh it, place it in a container, add a blank solution to dissolve it, and place it in a volumetric bottle; accurately measure the isomer reference solution stock solution, place it in the volumetric bottle, add the blank solution to dilute it, shake it well, and obtain it. Specifically: take about 10 mg of the Fmoc-Val-OH reference substance, accurately weigh it, place it in a suitable container, add an appropriate amount of blank solution to dissolve it, and place it in a 10 ml volumetric bottle; accurately measure 5 ml of the isomer reference solution stock solution, place it in the volumetric bottle, add the blank solution to dilute it to the scale, shake it well, and obtain it.

[0020] Further, the preparation method of the isomer reference solution stock solution is as follows: take Fmoc-D-Val-OH, accurately weigh it, place it in a container, add a blank solution to dissolve and dilute it, shake it well, accurately measure the solution, place it in a volumetric bottle, add a blank solution to dilute it, shake it well, and obtain it. Specifically: take about 10 mg of Fmoc-D-Val-OH, accurately weigh it, place it in a suitable container, add a blank solution to dissolve and dilute it to 100 ml, shake it well, accurately measure 1 ml of the solution, place it in a 25 ml volumetric bottle, add a blank solution to dilute it to the scale, shake it well, and obtain it.

[0021] Compared with the prior art, the technical effects created by the present invention are embodied in:

[0022] This application uses conventional reverse phase solvents. The Cellu-DR chiral chromatographic column separates the isomers of protected amino acids, and finally obtains a method for separating and determining Fmoc-L-Val-OH and its isomers. When the method of the present application is used for separation, the separation degree of each component under this chromatographic condition is greater than 1.5, the separation is good, the baseline is stable, the impurity separation effect meets the requirements of the pharmacopoeia, the specificity is good, the sensitivity is high, the shortcomings of the prior art are overcome, and a reference is provided for the development of analytical methods for other types of protected amino acids. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the chromatogram of Fmoc-L-Val-OH reference solution.

[0024] Figure 2 This is the chromatogram of Fmoc-D-Val-OH reference solution.

[0025] Figure 3 is the solution chromatogram of the method system suitability.

[0026] Figure 4 This is the chromatogram of the first injection precision result.

[0027] Figure 5 This is the chromatogram of the second injection precision result.

[0028] Figure 6 This is the chromatogram of the injection precision result of the third shot.

[0029] Figure 7 This is the chromatogram of the 4th injection precision result.

[0030] Figure 8 This is the chromatogram of the 5th injection precision result.

[0031] Fig. 9 This is the chromatogram of the 6th injection precision result.

[0032] Fig.10 This is the chromatogram of the first injection result at the quantitative limit concentration.

[0033] Fig.11 This is the chromatogram of the second injection result at the quantitative limit concentration.

[0034] Fig.12 This is the chromatogram of the third injection result at the quantitative limit concentration.

[0035] Fig.13 This is the chromatogram of the fourth injection result at the quantitative limit concentration.

[0036] Fig.14 This is the chromatogram of the fifth injection result at the quantitative limit concentration.

[0037] Fig.15 This is the chromatogram of the 6th injection result at the quantitative limit concentration.

[0038] Fig.16 This is the chromatogram of the first injection result at the 50% concentration limit.

[0039] Fig.17 This is the chromatogram of the second injection result with a concentration limit of 50%.

[0040] Fig.18 This is the chromatogram of the 3rd injection result with a concentration limit of 50%.

[0041] Fig.19 This is the chromatogram of the first injection result with a 100% concentration limit.

[0042] Fig. 20 This is the chromatogram of the second injection result with a 100% concentration limit.

[0043] Fig.21 This is the chromatogram of the 3rd injection result with 100% concentration limit.

[0044] Fig. 22 This is the chromatogram of the first injection result at the 150% concentration limit.

[0045] Fig.23 This is the chromatogram of the second injection result with a concentration limit of 150%.

[0046] Fig.24 This is the chromatogram of the 3rd injection result with a concentration limit of 150%.

[0047] Fig.25 This is the chromatogram of the first injection result at the 200% concentration limit.

[0048] Fig.26 This is the chromatogram of the second injection result at the 200% concentration limit.

[0049] Fig. 27 This is the chromatogram of the 3rd injection result at the 200% concentration limit. DETAILED DESCRIPTION

[0050] The technical solution of the present invention is further defined below in conjunction with specific implementation methods, but the scope of protection required is not limited to the description.

[0051] Example

[0052] The determination method of Fmoc-L-Val-OH and its isomers is carried out by liquid chromatography, and the chromatographic conditions are as follows:

[0053] Chromatographic column: Cellu-DR chiral chromatographic column (reverse phase chiral chromatographic column with cellulose-tris(3,5-dimethylphenylcarbamate) coated on silica surface as stationary phase). 4.6mm*250mm, 5um

[0054] Mobile phase: phosphoric acid aqueous solution with a pH of 2.00±0.1 as mobile phase A, methanol as mobile phase B;

[0055] Column temperature: 30±2℃; injection volume: 5.0±0.5μl;

[0056] Elution mode: isocratic elution;

[0057] Flow rate: 0.5±0.1ml / min;

[0058] Detection wavelength: 220nm;

[0059] Blank solution: methanol

[0060] The isocratic elution procedure is as follows:

[0061] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0.00 95.0 5.0 25.00 95.0 5.0

[0062] The specific operation cases are as follows:

[0063] Solution preparation:

[0064] pH 2.0 phosphoric acid aqueous solution: Measure 1L of Watsons water, add phosphoric acid to adjust the pH to 2.0, mix well and ultrasonicate for 30 minutes to obtain;

[0065] Methanol: Measure 1L of methanol, mix well and ultrasonicate for 30 minutes to obtain the final product;

[0066] Blank solution: methanol;

[0067] Isomer reference solution stock solution: take about 10 mg of Fmoc-D-Val-OH, accurately weigh it, place it in a suitable container, add blank solution to dissolve and dilute to 100 ml, shake well, accurately measure 1 ml of the solution, place it in a 25 ml volumetric flask, add blank solution to dilute to the scale, shake well, and obtain;

[0068] System suitability solution: Take about 10 mg of Fmoc-Val-OH reference substance, weigh accurately, place in a suitable container, add appropriate amount of blank solution to dissolve, and place in a 10 ml volumetric bottle; accurately measure 5 ml of isomer reference solution stock solution, place in the volumetric bottle, add blank solution to dilute to the scale, shake well, and obtain;

[0069] Test solution: Take about 10 mg of the test sample, weigh accurately, place in a suitable container, add blank solution to dissolve and dilute to 10 ml, shake well, and prepare two in parallel;

[0070] According to the above chromatographic conditions, after the chromatographic system is stable, measure in sequence according to the following procedures:

[0071] Blank solution: 1 to 2 injections;

[0072] System suitability solution: 1 injection;

[0073] Test solution, double sample single injection.

[0074] Experimental results:

[0075]

[0076] Fmoc-L-Val-OH reference solution: see the results Figure 1 .

[0077] Fmoc-D-Val-OH reference solution: see the results Figure 2 .

[0078] Method System Suitability Solution: Results are shown in Figure 3 .

[0079] The main component and isomers were mixed and injected, and the separation degree of each component was greater than 1.5 under this chromatographic condition, indicating good separation.

[0080] In order to determine the stability of the method, the method's injection precision, linearity and solution stability were confirmed.

[0081] Injection precision confirmation experiment:

[0082] The system suitability solution was injected continuously for 6 times, and the injection precision of the method was evaluated by judging the RSD values ​​of the peak area and retention time of the 6 injections.

[0083] The experimental results are as follows:

[0084]

[0085]

[0086] The results of the first injection precision are shown in Figure 4 ;

[0087] The results of the second injection precision are shown in Figure 5 ;

[0088] The results of the third injection precision are shown in Figure 6 ;

[0089] The results of the 4th injection precision are shown in Figure 7 ;

[0090] The results of injection precision for the 5th injection are shown in Figure 8 ;

[0091] The results of injection precision for the 6th injection are shown in Fig. 9 .

[0092] Quantitation limit concentration confirmation experiment:

[0093] Stock solution of reference substance: take about 10 mg of Fmoc-Val-OH reference substance, weigh accurately, place in a suitable container, add blank solution to dissolve and dilute to 100 ml, shake well, and obtain;

[0094] Isomer reference solution stock solution: Take about 10 mg of Fmoc-D-Val-OH, weigh accurately, place in a suitable container, add blank solution to dissolve and dilute to 100 ml, shake well, and obtain;

[0095] Quantitative limit solution: Pipette appropriate amount of Fmoc-D-Val-OH isomer reference solution stock solution and Fmoc-Val-OH reference substance solution stock solution into the same volumetric flask, dilute gradually with blank solution, prepare a solution of a certain concentration and inject it. The S / N of the main component is between 8 and 12, which is the quantitative limit solution;

[0096] The results are as follows:

[0097]

[0098]

[0099] The specific quantitative limit concentration injection results of 6 injections are shown in the table below. Figure 10-15 .

[0100] Linearity confirmation experiment:

[0101] Solution preparation:

[0102] Blank solution: methanol.

[0103] Stock solution of reference substance: take about 10 mg of Fmoc-Val-OH reference substance, weigh accurately, place in a suitable container, add blank solution to dissolve and dilute to 100 ml, shake well, and obtain;

[0104] Isomer reference solution stock solution: Take about 10 mg of Fmoc-D-Val-OH reference substance, accurately weigh it, place it in a suitable container, add blank solution to dissolve and dilute to 100 ml, shake well, and obtain;

[0105] Linear solution stock solution: Accurately measure 2 ml of the above reference solution stock solution and isomer reference solution stock solution, place them in the same 50 ml volumetric flask, add blank solution to dilute to the scale, shake well, and obtain;

[0106] The linear solutions were prepared as follows: quantitative limit solution, linear solution (50%), linear solution (100%), linear solution (150%), linear solution (200%), 3 injections per sample, quantitative limit data referenced quantitative limit confirmation experiment;

[0107]

[0108]

[0109] The experiment was carried out according to the above chromatographic conditions, and the results are summarized as follows:

[0110]

[0111] 50% concentration limit spectrum 3 injection results see Figure 16-18 .

[0112] 100% concentration limit spectrum 3 injection results see Figure 19-21 .

[0113] 150% concentration limit spectrum 3 injection results see Figure 22-24 .

[0114] 200% concentration limit spectrum 3 injection results see Figure 25-27 .

[0115] The above experiments all demonstrate that the stability and accuracy of the method of the present application are good.

[0116] Finally, it should be pointed out that the above embodiments are only representative examples of the present invention. Obviously, the technical solution of the present invention is not limited to the above embodiments, and there are many variations. All variations that can be directly derived or associated with the content disclosed by ordinary technicians in this field should be considered as the protection scope of the present invention.

Claims

1. A method for separating Fmoc-L-Val-OH and Fmoc-D-Val-OH by reverse phase separation, characterized in that: Liquid chromatography was used for determination, and the chromatographic conditions were as follows: Chromatographic column: Cellu-DR chiral chromatographic column, its specifications are: 4.6mm*250mm, 5um. Mobile phase: Aqueous phosphoric acid solution with a pH of 2.00±0.1 was used as mobile phase A, and methanol was used as mobile phase B.

2. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: The flow rate is 0.5±0.1ml / min and the detection wavelength is 220nm.

3. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: The column temperature is 30±2℃ and the injection volume is 5.0±0.5 μL.

4. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: Its blank solution: methanol.

5. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: Said Cellu-DR chiral chromatographic column is a reverse phase chiral chromatographic column with the stationary phase being cellulose-tris(3,5-dimethylphenylcarbamate) coated on the silica surface.

6. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: The elution method is isocratic elution, and the elution procedure is as follows:

7. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: The preparation method of the test solution is as follows: take the test sample, weigh it accurately, put it in a container, add blank solution to dissolve and dilute it, shake well, and obtain it.

8. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 1, characterized in that: The method for preparing the system adaptability solution is as follows: take the Fmoc-Val-OH reference substance, accurately weigh it, place it in a container, add the blank solution to dissolve it, and place it in a volumetric bottle; accurately measure the isomer reference solution stock solution, place it in the volumetric bottle, add the blank solution to dilute it, shake well, and obtain it.

9. The method for reverse phase separation of Fmoc-L-Val-OH and Fmoc-D-Val-OH according to claim 8, characterized in that: The preparation method of the isomer reference solution stock solution is as follows: take Fmoc-D-Val-OH, accurately weigh it, put it in a container, add blank solution to dissolve and dilute it, shake it well, accurately measure the solution, put it in a volumetric bottle, add blank solution to dilute it, shake it well, and obtain it.

Citation Information

Cited By

  • Method for analyzing purity and related substances of fluorenylmethoxycarbonyl-L-valine

    CN119901859A

  • Detection method for protecting amino acid enantiomer

    CN120559131A